Abstract
Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Current Pharmaceutical Design
Title: Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Volume: 17 Issue: 33
Author(s): Mattia Mori, Fabrizio Manetti and Maurizio Botta
Affiliation:
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Abstract: Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Export Options
About this article
Cite this article as:
Mori Mattia, Manetti Fabrizio and Botta Maurizio, Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220972
DOI https://dx.doi.org/10.2174/138161211798220972 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway
Current Pharmaceutical Design From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets MALDI Mass Spectrometry Imaging, from its Origins up to Today: The State of the Art
Combinatorial Chemistry & High Throughput Screening Inhibitors of the Hedgehog Signal Transduction Pathway
Current Cancer Therapy Reviews Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Recent Advances in Design of Potential Quinoxaline Anti-Infectives
Current Medicinal Chemistry Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology